PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]